Literature DB >> 10770181

Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children.

M K Karvonen1, M Koulu, U Pesonen, M I Uusitupa, A Tammi, J Viikari, O Simell, T Rönnemaa.   

Abstract

The Leu7Pro gene variant of the signal peptide part of neuropeptide Y (NPY), has been shown to affect cholesterol metabolism in obese adults. This study investigates whether the Leu7Pro polymorphism in the prepro-NPY has an impact on serum lipid concentrations in preschool-aged children at 5 and 7 yr of age. As birth weight may influence future lipid values, we also investigated whether Leu7Pro polymorphism is associated with birth weight. The study comprised 688 children participating in the Special Turku Coronary Risk Factor Intervention Project. Fasting lipid concentrations were determined first at the age of 5 yr and again at the age of 7 yr. The Leu7Pro polymorphism was not associated with serum total or low density lipoprotein cholesterol values in boys or in girls. However, Pro7 substitution in prepro-NPY was constantly associated with 14-17% higher mean serum triglyceride values in the boys at the ages of 5 and 7 yr (P = 0.023). In addition, boys with the Pro7 substitution had, on the average, a 193-g higher birth weight than boys homozygous for Leu7 (P = 0.03). The Leu7Pro polymorphism may thus be linked with serum triglyceride concentrations, but not with serum cholesterol concentrations, in gender-specific manner in preschoolers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770181     DOI: 10.1210/jcem.85.4.6521

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  NPY and stress 30 years later: the peripheral view.

Authors:  Dalay Hirsch; Zofia Zukowska
Journal:  Cell Mol Neurobiol       Date:  2012-01-24       Impact factor: 5.046

2.  Medical sequencing at the extremes of human body mass.

Authors:  Nadav Ahituv; Nihan Kavaslar; Wendy Schackwitz; Anna Ustaszewska; Joel Martin; Sybil Hebert; Heather Doelle; Baran Ersoy; Gregory Kryukov; Steffen Schmidt; Nir Yosef; Eytan Ruppin; Roded Sharan; Christian Vaisse; Shamil Sunyaev; Robert Dent; Jonathan Cohen; Ruth McPherson; Len A Pennacchio
Journal:  Am J Hum Genet       Date:  2007-03-05       Impact factor: 11.025

3.  Association of Neuropeptide-Y (NPY) and Interleukin-1beta (IL1B), Genotype-Phenotype Correlation and Plasma Lipids with Type-II Diabetes.

Authors:  Roma Patel; Mitesh Dwivedi; Mohmmad Shoab Mansuri; Naresh C Laddha; Ami Thakker; A V Ramachandran; Rasheedunnisa Begum
Journal:  PLoS One       Date:  2016-10-17       Impact factor: 3.240

4.  Acute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in mice.

Authors:  Janine J Geerling; Yanan Wang; Louis M Havekes; Johannes A Romijn; Patrick C N Rensen
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

5.  Neuropeptide Y in the noradrenergic neurons induces the development of cardiometabolic diseases in a transgenic mouse model.

Authors:  Suvi T Ruohonen; Ullamari Pesonen; Eriika Savontaus
Journal:  Indian J Endocrinol Metab       Date:  2012-12

6.  Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.

Authors:  Carmine Zoccali; Alberto Ortiz; Inga Arune Blumbyte; Sarina Rudolf; Annette G Beck-Sickinger; Jolanta Malyszko; Goce Spasovski; Sol Carriazo; Davide Viggiano; Justina Kurganaite; Vaiva Sarkeviciene; Daiva Rastenyte; Andreja Figurek; Merita Rroji; Christopher Mayer; Mustapha Arici; Gianvito Martino; Gioacchino Tedeschi; Annette Bruchfeld; Belinda Spoto; Ivan Rychlik; Andrzej Wiecek; Mark Okusa; Giuseppe Remuzzi; Francesca Mallamaci
Journal:  Nephrol Dial Transplant       Date:  2021-12-28       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.